Skip to main content
SpringerLink
Log in

Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica: l’esperienza della ASL della provincia di Alessandria

Evaluation of dosages and costs associated with the use of erythropoietin receptor agonists in the treatment of anemia in patients with chronic kidney disease: the Local Health Unit of Alessandria experience

  • Published:
PharmacoEconomics Italian Research Articles

Abstract

Introduction

Anemia represents one of the most frequent and debilitating disease associated with chronic kidney disease (CKD). If anemia is untreated, the quality of life is reduced and survival shortened. Epoetin (α o β) and darbepoetin-α are Erythropoietin Receptor Agonists (ERAs) indicated for the treatment of anemia in patients with CKD.

Materials and methods

Data for this retrospective study were derived from the administrative database of a middle-size (about 450,000 beneficiaries) Local Health Unit in Northern Italy. A sample was built by selecting all patients who, between 2007 and 2008, had a diagnosis of CKD and received at least two prescriptions for ERA. The study evaluated the durations of treatments, the RDDs (Received Daily Doses), the Dose Conversion Ratio (DCR) between epoetin (α o β) and darbepoetin-α, and the weekly costs associated with either treatment.

Results

The original sample consisted of 378 patients (mean age: 75.04 years, 51.9% males). The mean duration of treatment was 24.97 weeks for epoetin (α o β) and 25.12 weeks for darbepoetin-α (p = 0.92). The mean weighted relative RDD was 3.28 µg for darbepoetin-α (mean weekly dosage: 22.99 µg) and 601.14 IU for epoetin (α o β) [mean weekly dosage: 4,207.99 IU], with a DCR between epoetin (α o β) and darbepoetin-α of 183.01 IU: 1 µg. The weekly mean cost of treatment was €37.52 for patients treated with epoetin (α o β) and €48.07 for patients treated with darbepoetin-α (p = 0.003).

Discussion and conclusions

Based on data from the Local Health Unit of Alessandria, we performed an analysis focused on the use of ERAs in the treatment of anemia in patients with CKD. The weekly mean cost of treatment and the DCR between epoetin (α o β) and darbepoetin-α resulted was consistent with a previous national study of drug utilization. Epoetin (α o β) is a cost-saving strategy compared with darbepoetin-α in the treatment of anemia in patients with chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002; 87: 1341–53

    Article  PubMed  CAS  Google Scholar 

  2. Leitgeb C, Pecherstorfer M, Fritz E, et al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535–42

    Article  PubMed  CAS  Google Scholar 

  3. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34: 4–12

    PubMed  CAS  Google Scholar 

  4. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43–6

    PubMed  CAS  Google Scholar 

  5. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of hemoglobin target. Am J Kidney Dis 2007; 50: 471–530

    Article  Google Scholar 

  6. Singh AK, Szczech L, Tang K, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98

    Article  PubMed  CAS  Google Scholar 

  7. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–84

    Article  PubMed  Google Scholar 

  8. Cotter D, Thamer M, Narasimhan K, et al. Translating epoetin research into practice: the role of government0 and the use of scientific evidence. Health Aff (Millwood) 2006; 25: 1249–59

    Article  Google Scholar 

  9. Aljama P, Bommer J, Canaud B, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16 (Suppl. 3): 22–8

    Article  PubMed  CAS  Google Scholar 

  10. Triolo G, Italian Society of Nephrology. Guidelines for the treatment of anemia in chronic renal failure. G Ital Nefrol 2003; 20 (Suppl. 24): S61–82

    PubMed  Google Scholar 

  11. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl. 2): ii1–47

    Article  PubMed  Google Scholar 

  12. Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin 2006; 22: 2329–36

    Article  PubMed  Google Scholar 

  13. Reichardt B. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. J Clin Pharm Ther 2006; 31: 503–12

    Article  PubMed  CAS  Google Scholar 

  14. Frenken LA, Verberckmoes R, Michielsen P, et al. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 1989; 4: 782–6

    PubMed  CAS  Google Scholar 

  15. Schaefer RM, Schaefer L, Heidland A. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients. Przegl Lek 1992; 49: 41–2

    PubMed  CAS  Google Scholar 

  16. Albertazzi A, Di Liberato L, Daniele F, et al. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs 1998; 21: 12–8

    PubMed  CAS  Google Scholar 

  17. Horl WH. A need for an individualized approach to endstage renal disease patients. Nephrol Dial Transplant 2002; 17 (Suppl. 6): 17–21

    Article  PubMed  Google Scholar 

  18. Macdougall IC. Erythropoietin and renal failure. Curr Hematol Rep 2003; 2: 459–64

    PubMed  Google Scholar 

  19. Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005; 20: 2146–52

    Article  PubMed  CAS  Google Scholar 

  20. Rossert J, Froissart M, Jacquot C. Anemia management and chronic renal failure progression. Kidney Int Suppl 2005; 99: $76–81

    Article  Google Scholar 

  21. Dean BB, Dylan M, Gano Air, et al. Erythropoiesisstimulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981–7

    Article  PubMed  CAS  Google Scholar 

  22. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 (Suppl. 3): 3–13

    Article  PubMed  Google Scholar 

  23. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204–14

    Article  PubMed  CAS  Google Scholar 

  24. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303–20

    Article  PubMed  CAS  Google Scholar 

  25. Pohl G, Ludwig H. Supportive treatment for anemic cancer patients. Wiener Medizinische Wochenschrift 2004; 154(9–10): 226–34

    Article  PubMed  Google Scholar 

  26. Locatelli F, Olivares J, Walzer R, et al. Novel erythopoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741–7

    Article  PubMed  CAS  Google Scholar 

  27. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia in chronic kidney disease. Clin Nephrol 2004; 60: 392–405

    Google Scholar 

  28. Stone WJ, Graber SE, Krantz SB, et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci 1988; 296: 171–9

    Article  PubMed  CAS  Google Scholar 

  29. Beusterien KM, Nissenson AR, Port FK, etal. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763–73

    PubMed  CAS  Google Scholar 

  30. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000; 11: 335–42

    PubMed  CAS  Google Scholar 

  31. Ravasio R, Cerra C, Fratino P. Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica. PharmacoEconomics-Italian Research Articles 2008; 10: 161–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health Italy Ltd, Milano, Italia

    R. Ravasio

  2. Dipartimento del Farmaco, Azienda Sanitaria Locale di Alessandria, Italia

    M. D’Orsi, G. F. Zuccotti, A. Girlanda & D. Cantù

  3. SOC Controllo di gestione, Azienda Sanitaria Locale di Alessandria, Italia

    C. Buffa & M. De Petris

Authors
  1. R. Ravasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. D’Orsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. F. Zuccotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Girlanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Cantù
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Buffa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. De Petris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Ravasio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravasio, R., D’Orsi, M., Zuccotti, G.F. et al. Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica: l’esperienza della ASL della provincia di Alessandria. Pharmacoeconomics-Ital-Res-Articles 12, 167–174 (2010). https://doi.org/10.1007/BF03320674

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320674

Search

Navigation